Skip to main navigation Skip to search Skip to main content

A 12-month, randomized, rater & dose-blinded study to compare efficacy & safety of fingolimod administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing multiple sclerosis

Project: Research

Project Details

StatusFinished
Effective start/end date04/2/1308/2/19

Funding

  • Novartis Pharmaceuticals Corporation: $83,364.06